Abstract
Autism spectrum disorder (ASD) presents lifelong neurodevelopmental challenges and is diagnosed in early childhood. ASD is complex, has multiple causes, and is characterized by communication difficulties, impaired social interaction, and repetitive behaviors. Unfortunately, there are no specific biomarkers for diagnosis or effective treatments yet. However, nanomedicine offers promise for treating central nervous system (CNS) disorders conditions, including ASD. Nanomaterials can cross the blood–brain barrier, target specific cells, disseminate in brain tissue, and serve as carriers for therapeutics. This review emphasizes the importance and potential of nanomedicine, current pharmacological treatments for ASD, challenges in drug development, and recent medical approaches based on nanotechnology to overcome the blood brain barrier and deliver CNS therapeutics. Neurobiological research for future nanomedicine applications will also be highlighted.
This is a preview of subscription content, log in via an institution to check access.
References
Ayub, A., & Wettig, S. (2022). An overview of nanotechnologies for drug delivery to the brain. Pharmaceutics, 14, 224. https://doi.org/10.3390/pharmaceutics14020224
Baker, E., & Jeste, S. S. (2015). Diagnosis and management of autism spectrum disorder in the era of genomics. Pediatric Clinics of North America, 62, 607–618. https://doi.org/10.1016/j.pcl.2015.03.003
Baldwin, D. S., Anderson, I. M., Nutt, D. J., et al. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28, 403–439. https://doi.org/10.1177/0269881114525674
Baranova, J., Dragunas, G., Botellho, M. C. S., et al. (2021). Autism spectrum disorder: Signaling pathways and prospective therapeutic targets. Cellular and Molecular Neurobiology, 41, 619–649. https://doi.org/10.1007/s10571-020-00882-7
Baribeau, D., Vorstman, J., & Anagnostou, E. (2022). Novel treatments in autism spectrum disorder. Current Opinion in Psychiatry, 35, 101–110. https://doi.org/10.1097/YCO.0000000000000775
Case-Smith, J., & Arbesman, M. (2008). Evidence-based review of interventions for autism used in or of relevance to occupational therapy. American Journal of Occupational Therapy, 62, 416–429. https://doi.org/10.5014/ajot.62.4.416
Choong, C.-J., Baba, K., & Mochizuki, H. (2016). Gene therapy for neurological disorders. Expert Opinion on Biological Therapy, 16, 143–159. https://doi.org/10.1517/14712598.2016.1114096
Guo, Z.-H., Khattak, S., Rauf, M. A., et al. (2023). Role of nanomedicine-based therapeutics in the treatment of CNS disorders. Molecules, 28, 1283. https://doi.org/10.3390/molecules28031283
Ha, S., Sohn, I.-J., Kim, N., et al. (2015). Characteristics of Brains in autism spectrum disorder: Structure, function and connectivity across the lifespan. Experimental Neurobiology, 24, 273–284. https://doi.org/10.5607/en.2015.24.4.273
He, X., Xie, J., Zhang, J., et al. (2022). Acid-responsive dual-targeted nanoparticles encapsulated aspirin rescue the immune activation and phenotype in autism spectrum disorder. Advancement of Science, 9, 2104286. https://doi.org/10.1002/advs.202104286
Hume, K., Steinbrenner, J. R., Odom, S. L., et al. (2021). Evidence-based practices for children, youth, and young adults with autism: Third generation review. Journal of Autism and Developmental Disorders, 51, 4013–4032. https://doi.org/10.1007/s10803-020-04844-2
Jeremy Willsey, A., & State, M. W. (2015). Autism spectrum disorders: From genes to neurobiology. Current Opinion in Neurobiology, 30, 92–99. https://doi.org/10.1016/j.conb.2014.10.015
Jiang, C.-C., Lin, L.-S., Long, S., et al. (2022). Signalling pathways in autism spectrum disorder: Mechanisms and therapeutic implications. Signal Transduction and Targeted Therapy, 7, 229. https://doi.org/10.1038/s41392-022-01081-0
Khalaj, R., Hajizadeh Moghaddam, A., & Zare, M. (2018). Hesperetin and it nanocrystals ameliorate social behavior deficits and oxido-inflammatory stress in rat model of autism. International Journal of Developmental Neuroscience, 69, 80–87. https://doi.org/10.1016/j.ijdevneu.2018.06.009
Loo, L., Simon, J. M., Xing, L., et al. (2019). Single-cell transcriptomic analysis of mouse neocortical development. Nature Communications, 10, 134. https://doi.org/10.1038/s41467-018-08079-9
Lv, H., Gu, X., Shan, X., et al. (2022). Nanoformulated bumetanide ameliorates social deficiency in BTBR mice model of autism spectrum disorder. Frontiers in Immunology, 13, 870577. https://doi.org/10.3389/fimmu.2022.870577
Masi, A., DeMayo, M. M., Glozier, N., & Guastella, A. J. (2017). An overview of autism spectrum disorder, heterogeneity and treatment options. Neuroscience Bulletin, 33, 183–193. https://doi.org/10.1007/s12264-017-0100-y
Meyre, D., Deliard, S., Vazquez, D., et al. (2018). Nanoparticles for use in treating a neuronal disorder and methods for preparing same. Patent Application WO2019121748A1.
Mittal, K. R., Pharasi, N., Sarna, B., et al. (2022). Nanotechnology-based drug delivery for the treatment of CNS disorders. Translational Neuroscience, 13, 527–546. https://doi.org/10.1515/tnsci-2022-0258
Nguyen, T. T., Dung Nguyen, T. T., Vo, T. K., et al. (2021). Nanotechnology-based drug delivery for central nervous system disorders. Biomedicine & Pharmacotherapy, 143, 112117. https://doi.org/10.1016/j.biopha.2021.112117
Perihan, C., Burke, M., Bowman-Perrott, L., et al. (2020). Effects of cognitive behavioral therapy for reducing anxiety in children with high functioning ASD: A systematic review and meta-analysis. Journal of Autism and Developmental Disorders, 50, 1958–1972. https://doi.org/10.1007/s10803-019-03949-7
Rhaman, Md. M., Islam, Md. R., Akash, S., et al. (2022). Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance. Frontiers in Cell and Developmental Biology, 10, 989471. https://doi.org/10.3389/fcell.2022.989471
Rojas, D. C., & Wilson, L. B. (2014). γ-band abnormalities as markers of autism spectrum disorders. Biomarkers in Medicine, 8, 353–368. https://doi.org/10.2217/bmm.14.15
Rossignol, D. A., & Frye, R. E. (2011). Melatonin in autism spectrum disorders: A systematic review and meta-analysis: Review. Developmental Medicine and Child Neurology, 53, 783–792. https://doi.org/10.1111/j.1469-8749.2011.03980.x
Sharma, S., Hucker, A., Matthews, T., et al. (2021). Cognitive behavioural therapy for anxiety in children and young people on the autism spectrum: A systematic review and meta-analysis. BMC Psychology, 9, 151. https://doi.org/10.1186/s40359-021-00658-8
Shuid, A. N., Jayusman, P. A., Shuid, N., et al. (2020). Update on atypicalities of central nervous system in autism spectrum disorder. Brain Sciences, 10, 309. https://doi.org/10.3390/brainsci10050309
Sinha, S., McGovern, R. A., & Sheth, S. A. (2015). Deep brain stimulation for severe autism: From pathophysiology to procedure. Neurosurgical Focus, 38, E3. https://doi.org/10.3171/2015.3.FOCUS1548
Spuch, C., Saida, O., & Navarro, C. (2012). Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent Patents on Drug Delivery & Formulation, 6, 2–18. https://doi.org/10.2174/187221112799219125
Srinivasan, S. M., Pescatello, L. S., & Bhat, A. N. (2014). Current perspectives on physical activity and exercise recommendations for children and adolescents with autism spectrum disorders. Physical Therapy, 94, 875–889. https://doi.org/10.2522/ptj.20130157
Steinbrenner, J. R., Hume, K., Odom, S. L., et al. (2020). Evidence-based practices for children, youth, and young adults with autism spectrum disorder: A comprehensive review. Frank Porter Graham Child Development Institute, University of North Carolina at Chapel Hill.
Stepanova, E., Dowling, S., Phelps, M., & Findling, R. L. (2017). Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialogues in Clinical Neuroscience, 19, 395–402. https://doi.org/10.31887/DCNS.2017.19.4/rfindling
Tarver, J., Palmer, M., Webb, S., et al. (2019). Child and parent outcomes following parent interventions for child emotional and behavioral problems in autism spectrum disorders: A systematic review and meta-analysis. Autism, 23, 1630–1644. https://doi.org/10.1177/1362361319830042
U.S. Department of Health and Human Services. (1999). Mental health: A report of the surgeon general. Washington, D.C: Public Health Service.
Weiss, L. D. (2008). Cognitive therapy for depressive disorders in children and adolescents. In A. Freeman, R. M. Jr. Reinecke, & J. A. Garcia (Eds.), Handbook of evidence-based therapies for children and adolescents: Bridging science and practice (pp. 251–266). Academic Press.
Wright, B., Sims, D., Smart, S., et al. (2011). Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: A randomised controlled crossover Trial. Journal of Autism and Developmental Disorders, 41, 175–184. https://doi.org/10.1007/s10803-010-1036-5
Yatawara, C. J., Einfeld, S. L., Hickie, I. B., et al. (2016). The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial. Molecular Psychiatry, 21, 1225–1231. https://doi.org/10.1038/mp.2015.162
Zaman, R. U., Mulla, N. S., Braz Gomes, K., et al. (2018). Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin. International Journal of Pharmaceutics, 548, 698–706. https://doi.org/10.1016/j.ijpharm.2018.07.043
Zeidan, J., Fombonne, E., Scorah, J., et al. (2022). Global prevalence of autism: A systematic review update. Autism Research, 15, 778–790. https://doi.org/10.1002/aur.2696
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics Approval
NA.
Consent to Participate
NA.
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Al-Dujaili, Z., Al Faraj, A. Would Nanoparticles Give Hope for the Treatment of Autism Spectrum Disorder?. Rev J Autism Dev Disord (2024). https://doi.org/10.1007/s40489-024-00452-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40489-024-00452-3